Nektar Therapeutics Income Statement - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.17 $0.51 (2.35%) NKTR stock closing price Jul 20, 2017 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Nektar Therapeutics stock price. In the income statement, an investor can check for important parameters like the topline, the bottomline, the EPS basic, dividends etc. Like any other income statement, the NKTR income statement also itemizes revenue, operating expenses, and profits for a quarter or year and reflects a QoQ revenue decline of $12.72M when compared to the same period in the past. One also needs to look at Nektar Therapeutics assets, operating expenses and Nektar Therapeutics free cash flow. The profit and loss statement shows revenue of $24.73M for 2017-Q1. Revenue has decreased by $12.72M QoQ for NKTR stock. View details of revenue and profits for Nektar Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4
Nektar Therapeutics Net Sales or Revenues
24.73M37.45M36.34M32.77M58.88M39.37M59.95M22.66M108.8M19.55M
Cost Of Goods Sold (COGS)6.13M6.61M7.03M7.7M8.87M8.37M6.76M10.53M8.44M6.31M
Nektar Therapeutics Gross Profit
18.59M30.85M29.3M25.06M50.01M31.02M53.19M12.12M100.35M13.26M
Research & Development Expense61.05M50.24M51.95M52.35M49.26M47.14M43.22M45.41M47.01M38.5M
Selling General & Admin Expense11.97M12.77M10.25M11.03M10.22M13.24M9.54M10.18M10.3M12.26M
Income Before Depreciation Depletion Amortization-54.43M-32.15M-32.9M-38.32M-9.48M-29.36M0.41M-43.46M43.04M-37.49M
Depreciation Depletion Amortization----------
Non Operating Income0.65M0.73M0.33M0.45M0.87M-13.73M0.89M0.24M0.21M0.29M
Interest Expense9.95M10.35M10.51M10.6M10.72M10.99M9.42M9.27M9.22M9.62M
Nektar Therapeutics Pretax Income
-63.73M-41.76M-43.08M-48.47M-19.33M-54.1M-8.11M-52.49M34.03M-46.82M
Provision for Income Taxes0.13M0.46M0.13M0.12M0.16M0.04M0.09M0.16M0.21M-1.13M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-63.87M-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Net Income (Profit/Loss)
-63.87M-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M
Average Shares used to compute Diluted EPS153.67M149.07M137.09M136.35M135.79M134.17M132.63M131.64M135.67M129.33M
Average Shares used to compute Basic EPS153.67M149.07M137.09M136.35M135.79M134.17M132.63M131.64M131.36M129.33M
Income Before Nonrecurring Items-63.87M-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M
Income from Nonrecurring Items----------
Nektar Therapeutics Earnings Per Share Basic Net
-0.42-0.28-0.32-0.36-0.14-0.40-0.06-0.400.26-0.35
Nektar Therapeutics Earnings Per Share Diluted Net
-0.42-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.35
EPS Diluted Before Nonrecurring Items-0.42-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.35
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:22
NKTR
The key things to look for in an income statement while doing Nektar Therapeutics stock analysis are:
  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth (See: Nektar Therapeutics revenue chart) implies that the company is growing, which has not been the case with Nektar Therapeutics. One must stay away from stocks whose revenues are declining.
  • Bottom line: Most businesses like Nektar Therapeutics try to improve their bottom line by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Nektar Therapeutics historical stock prices to check how the price has moved with time. .

Nektar Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
25.9491
Operating margin
-220.1
Net profit margin
-258.3
Dividend yield
0%